US · ATRC · MEDICAL - INSTRUMENTS & SUPPLIES
AtriCure, Inc. (ATRC) intrinsic value and stock valuation
$55.39as of 2026-11-21 · Mkt cap 2.11B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
AtriCure, Inc. DCF and intrinsic value
InvestorsCraft values ATRC with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from ATRC’s statements →
AtriCure, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $534.5M | $465.3M | $399.3M | $330.4M | $274.3M |
| Operating income | -$-3.45M | -$-40.01M | -$-26.68M | -$-42.67M | $55.2M |
| Net income | -$-11.45M | -$-44.7M | -$-30.44M | -$-46.47M | $50.2M |
| EPSd | -$-239.79K | -$-951.67K | -$-657.31K | -$-1.02M | $1.09M |
| Operating cash flow | $57.3M | $12.2M | $4.48M | -$-22.14M | -$-13.78M |
| Capital expenditure | -$-9.05M | -$-23.46M | -$-42M | -$-16.88M | -$-9.75M |
| Free cash flow | $48.3M | -$-11.26M | -$-37.51M | -$-39.02M | -$-23.53M |
| Total assets | $654.2M | $609.3M | $613.9M | $585.5M | $615.3M |
| Total debt | $88M | $76.5M | $74.5M | $74.6M | $75.7M |
| Net debt | -$-79.41M | -$-46.19M | -$-9.82M | $16.5M | $32M |
| Total equity | $491.9M | $461M | $466.2M | $456.8M | $483.8M |
| Cash and short-term investments | $167.4M | $122.7M | $137.3M | $121.1M | $119.1M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $534.5M | $465.3M | $399.3M | $330.4M | $274.3M |
| Cost of revenue | $136.8M | $117.8M | $98.9M | $84.4M | $68.5M |
| Gross profit | $397.7M | $347.5M | $300.4M | $245.9M | $205.9M |
| Research and development expenses | $90.2M | $96.2M | $73.9M | $57.3M | $48.5M |
| Selling, general and administrative expenses | $311M | $291.4M | $253.1M | $231.3M | $204.7M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | -$-102.5M |
| Operating expenses | $401.2M | $387.5M | $327.1M | $288.6M | $150.7M |
| Cost and expenses | $538M | $505.3M | $425.9M | $373.1M | $219.1M |
| Interest income | $4.48M | $4.43M | $3.79M | $1.99M | $470K |
| Interest expense | $5.88M | $6.41M | $6.92M | $4.99M | $4.92M |
| Depreciation and amortization | $20.5M | $18.7M | $14.8M | $11.7M | $10.4M |
| Ebitda | $16.3M | -$-18.53M | -$-8.11M | -$-29.5M | $65.8M |
| Operating income | -$-3.45M | -$-40.01M | -$-26.68M | -$-42.67M | $55.2M |
| Total other income/expenses, net | -$-6.72M | -$-3.66M | -$-3.16M | -$-3.53M | -$-4.82M |
| Income before tax | -$-10.16M | -$-43.67M | -$-29.85M | -$-46.2M | $50.4M |
| Income tax expense | $1.28M | $1.02M | $590K | $270K | $190K |
| Net income | -$-11.45M | -$-44.7M | -$-30.44M | -$-46.47M | $50.2M |
| Weighted average shares outstanding | $47.8M | $47M | $46.3M | $45.7M | $45.1M |
| Weighted average diluted shares outstanding | $47.8M | $47M | $46.3M | $45.7M | $46M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $167.4M | $122.7M | $137.3M | $121.1M | $119.1M |
| Net receivables | $66.7M | $60.3M | $52.5M | $42.7M | $33M |
| Inventory | $78.5M | $75.3M | $67.9M | $45.9M | $39M |
| Total current assets | $322.5M | $267.8M | $266.3M | $215.2M | $196.1M |
| Property, plant and equipment, net | $46M | $47.4M | $46.8M | $42.6M | $36.2M |
| Goodwill and intangible assets | $282.8M | $291.3M | $298.8M | $274.1M | $277.8M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $51.5M | $104.3M |
| Total non-current assets | $331.7M | $341.5M | $347.7M | $370.2M | $419.2M |
| Total assets | $654.2M | $609.3M | $613.9M | $585.5M | $615.3M |
| Accounts payable | $78.4M | $25M | $27.4M | $19.9M | $18.6M |
| Short-term debt | $3.12M | $2.81M | $2.53M | $5.47M | $1.76M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $81.5M | $73.4M | $74.6M | $58.4M | $56.5M |
| Long-term debt | $84.9M | $73.7M | $72M | $69.1M | $73.9M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $80.7M | $74.9M | $73.2M | $70.3M | $75.1M |
| Capital lease obligations | $11.5M | $11.9M | $11.4M | $14.4M | $15.9M |
| Total liabilities | $162.2M | $148.4M | $147.8M | $128.7M | $131.6M |
| Common stock | $50K | $50K | $50K | $50K | $50K |
| Retained earnings | -$-413.2M | -$-401.75M | -$-357.06M | -$-326.62M | -$-280.15M |
| Accumulated other comprehensive income (loss) | $570K | -$-1.03M | -$-990K | -$-4.1M | -$-950K |
| Total equity | $491.9M | $461M | $466.2M | $456.8M | $483.8M |
| Total investments | $0.00 | $0.00 | $53M | $114.5M | $179.8M |
| Total debt | $88M | $76.5M | $74.5M | $74.6M | $75.7M |
| Net debt | -$-79.41M | -$-46.19M | -$-9.82M | $16.5M | $32M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-11.45M | -$-44.7M | -$-30.44M | -$-46.47M | $50.2M |
| Depreciation and amortization | $20.5M | $18.7M | $14.8M | $11.7M | $10.4M |
| Stock-based compensation | $44.7M | $40.4M | $35.7M | $28.8M | $28.1M |
| Change in working capital | -$-4.29M | -$-18.36M | -$-18.24M | -$-18.88M | -$-4.85M |
| Accounts receivable | -$-5.61M | -$-8.3M | -$-9.87M | -$-8.99M | -$-10.09M |
| Inventory | -$-2.26M | -$-7.74M | -$-21.83M | -$-7.3M | -$-4.27M |
| Accounts payable | -$-960K | -$-1.53M | $6.18M | $2.68M | $4.71M |
| Net cash provided by operating activities | $57.3M | $12.2M | $4.48M | -$-22.14M | -$-13.78M |
| Investments in property, plant and equipment | -$-9.05M | -$-11.46M | -$-12M | -$-16.88M | -$-9.75M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-44.01M | -$-33.26M |
| Net cash used for investing activities | -$-14.55M | $30.2M | $21.8M | $44M | $23.5M |
| Common stock issued | $7.29M | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-11.16M | -$-6.95M | -$-6.56M | -$-12.2M | -$-18.01M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $1.18M | -$-3.6M | -$-30K | -$-7.06M | -$-7.64M |
| Net change in cash | $44.7M | $38.4M | $26.2M | $14.5M | $1.71M |
| Cash at end of period | $167.4M | $122.7M | $84.3M | $58.1M | $43.7M |
| Operating cash flow | $57.3M | $12.2M | $4.48M | -$-22.14M | -$-13.78M |
| Capital expenditure | -$-9.05M | -$-23.46M | -$-42M | -$-16.88M | -$-9.75M |
| Free cash flow | $48.3M | -$-11.26M | -$-37.51M | -$-39.02M | -$-23.53M |
Line items
Line items
Line items
About AtriCure, Inc.
AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX Pen, uniquely enable surgeons to evaluate cardiac arrhythmias, conduct temporary pacing, sensing, and stimulation, and perform tissue ablation with a single device. The Coolrail device facilitates the creation of longer linear ablation lines. For varying lengths of linear ablations, the CryoICE Cryoablation System is available. Furthermore, the EPi-Sense Guided Coagulation System is a single-use solution for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure also provides systems for cardiac appendage management and soft-tissue closure. The AtriClip System is an implantable device accompanied by a disposable applier, while the LARIAT System offers a suture-based solution for soft-tissue closure, compatible with various anatomical shapes. Additionally, AtriCure offers supplementary surgical tools including Lumitip Dissectors, designed to separate tissues for optimal access, Glidepath guides for precise clamp placement, and Subtle Cannulas facilitating access for EPi-Sense catheters. A suite of reusable cardiac surgery instruments, crucial for procedures involving heart valve repair or replacement, is also available. The company distributes its offerings through a combination of independent distributors and direct sales personnel. Founded in 2000, AtriCure maintains its headquarters in Mason, Ohio.
- CEO
- Michael H. Carrel
- Employees
- 1.35K
- Beta
- 1.25
Explore
Frequently asked questions
What is the intrinsic value of AtriCure, Inc. (ATRC)?
AtriCure, Inc. (ATRC) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is ATRC undervalued?
ATRC trades at a price of $55.39 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.